-
Mashup Score: 3
Panelists discuss data from the ADEPT trial, considerations regarding ports, and their hopes for the future of breast cancer treatment.
Source: cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Panel Discusses the Evolution of Therapy for HER2-Positive Breast Cancer | Cancer Nursing Today - 27 day(s) ago
Panelists discuss how therapy for HER2-positive breast cancer has evolved, and if indefinite therapy is still needed for certain patients.
Source: cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Breast Cancer Roundtable | Cancer Nursing Today - 1 month(s) ago
View roundtable discussions on breast cancer research and clinical insights from oncology nursing experts.
Source: cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4How to Address Time Toxicity, Quality-of-Life Concerns in Patients With Breast Cancer | Cancer Nursing Today - 1 month(s) ago
Panelists discuss how administration routes can affect time toxicity and quality of life in patients undergoing therapy for HER2-positive breast cancer.
Source: cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Panel Discusses the Evolution of Therapy for HER2-Positive Breast Cancer | Cancer Nursing Today - 2 month(s) ago
Panelists discuss how therapy for HER2-positive breast cancer has evolved, and if indefinite therapy is still needed for certain patients.
Source: cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Breast Cancer Roundtable | Cancer Nursing Today - 2 month(s) ago
View roundtable discussions on breast cancer research and clinical insights from oncology nursing experts.
Source: cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Digital Supplement: SABCS Meeting Highlights 2023 - The ASCO Post - 2 month(s) ago
Studies presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) significantly moved the needle forward in our treatment of breast cancer. We are increasingly learning how to stratify risk, so we can optimize therapy and minimize our patients’ exposure to treatments that will not be… Adding the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) to the HER2-targeted agent tucatinib extended progression-free survival by about 2 months vs treatment with T-DM1 alone among patients with
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Outcomes of Breast Cancer Screening Strategies Based on Cancer Intervention and Surveillance Modeling Network Estimates - 3 month(s) ago
Background There is ongoing debate about recommendations for breast cancer screening strategies, specifically regarding the frequency of screening and the age at which to initiate screening. Purpose To compare estimates of breast cancer screening outcomes published by the Cancer Intervention and Surveillance Modeling Network (CISNET) to understand the benefits and risks of different screening scenarios. Materials and Methods Modeling estimates published by CISNET are based on hypothetical cohorts in the United States and compare women, starting at 40 years of age, who do and do not undergo breast cancer screening with mammography. The four scenarios assessed in this study, of multiple possible scenarios, were biennial screening ages 50–74 years (2009 and 2016 U.S. Preventive Services Task Force [USPSTF] recommendations), biennial screening ages 40–74 years (2023 USPSTF draft recommendation), annual screening ages 40–74 years, and annual screening ages 40–79 years. For each scenario, CI
Source: pubs.rsna.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Breast Cancer Incidence by Race, Stage, and Hormone Receptor Status in U.S. Women - The ASCO Post - 3 month(s) ago
In a study reported in JAMA Network Open, Xu et al identified incidence of primary invasive breast cancer according to race/ethnicity, disease stage, and hormone receptor status among U.S. women with breast cancer aged 20 to 49 years diagnosed between 2000 and 2019. The study used data from 17 registries of the SEER (Surveillance, Epidemiology, and End Results) program on women aged 20 to 49 years diagnosed from 2000 to 2019. Among 217,815 eligible women included in the analysis, 126,960 (58.3%) were
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
▶️ What does the future hold for the treatment of HER2+ breast cancer? 🎙️ Experts from @MSKCancerCenter, @NYOHPC, @LifespanHlthSys & Florida Cancer Specialists shared their insights during a roundtable discussion. ➡️ Watch now: https://t.co/sVPFNOq1Tk #bcsm #breastcancer https://t.co/VhGBju5zEC